MagicRNA Biotechnology
HN2301 delivers CD19 CAR mRNA using engineered T-cell-targeted LNPs. MagicRNA reports first-in-human SLE findings published in the New England Journal of Medicine. The older English homepage’s IND-enabling description is not used to override the later human-study disclosure.
Corporate information
- Company entity
- MagicRNA Biotechnology
- Headquarters / principal office
- No verified public location identified
- Founded
- 2021 ↗
- Ownership / capital status
- PrivateSeries B ↗
- Official corporate reference
- https://magicrna.com/company/114.html ↗
- Latest financing / award identified
- 2026-08-13 · Series B · Hundreds of millions of yuan; exact amount not disclosed ↗
- LinkedIn company page
- Independent company page not verified
Disclosed equity event found in this review; not a claim that no later undisclosed event exists.
Profile review: 2026-11-04 · Fields retain their individual source dates. Undisclosed values are not zero; early or historical events do not establish the latest financing. Awards and acquisitions are distinguished from equity rounds.
Start with public sources and capability boundaries; company claims are not independent certification.
Ask AI ↗Public evidence snapshot
HN2301 delivers CD19 CAR mRNA using engineered T-cell-targeted LNPs. MagicRNA reports first-in-human SLE findings published in the New England Journal of Medicine. The older English homepage’s IND-enabling description is not used to override the later human-study disclosure.
This profile is a research snapshot, not a company endorsement. Check original sources for current information.
Original sources
- MagicRNA's First-in-Human Clinical Data Demonstrating Feasibility of In Vivo CAR T Therapy in Systemic Lupus Erythematosus Published in The New England Journal of Medicine.-Company News-Shenzhen MagicRNA Biotechnology Co., Ltd — official page checked
- Company financing announcement